Worcester, USA - 25 Sep `19Dermavant Sciences: Cerdulatinib Gel

Official Title: A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo. 

In Brief: Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks

Ages Eligible:  18 Years to 70 Years

Start Date: September 25, 2019

Completion Date (estimated): July 2020

Status: Active, recruiting

Study ID

  • ClinicalTrials.gov: NCT04103060
  • Other Study ID Numbers: DMVT-502-2101

Location: Dermavant Investigational Site: Worcester, Massachusetts, United States, 01605

Contact: To learn more about this study, you or your doctor may contact Dermavant Sciences by phone +1-480-666-0844 or email dermavantclinicaltrials@dermavant.com. Please refer to this study by its ClinicalTrials.gov identifier (NCT number)

FAQOther Questions

  • Is there a special diet for vitiligo?

    In short, no.  Some people find that certain foods may worsen their vitiligo symptoms or that others may improve their skin condition. We found no scientific evidence that a sp...

  • Is vitiligo contagious?

    Vitiligo is NOT contagious. It cannot be passed on or caught from touching someone with vitiligo, shaking hands, swimming in the same pool, sharing towels, sitting next to someo...

  • What tests should be done?

    A well-trained dermatologist should be able to diagnose vitiligo and distinguish it from contact leukoderma or more than twenty other conditions with similar skin appearance bas...